(Q37693135)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20158283%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

review article

1 reference

title

Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20158283%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

Apostolos I. Hatzitolios

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20158283%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

Yiannis S Chatzizisis

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20158283%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Konstantinos C Koskinas

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20158283%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Gesthimani Misirli

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20158283%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Christos Vaklavas

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20158283%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

George D Giannoglou

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20158283%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

publication date

1 March 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20158283%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20158283%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20158283%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20158283%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

171-187

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20158283%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.2165/11319380-000000000-00000

18 January 2020

exact match

0 references

cites work

A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin

1 reference

https://api.crossref.org/works/10.2165%2F11319380-000000000-00000

HIV protease inhibitors stimulate hepatic triglyceride synthesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11319380-000000000-00000

Ezetimibe and statin-associated myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11319380-000000000-00000

Ezetimibe-associated myopathy in monotherapy and in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11319380-000000000-00000

Colesevelam hydrochloride-ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11319380-000000000-00000

Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs

21 January 2018

1 reference

12 December 2020

An assessment of statin safety by muscle experts

1 reference

12 December 2020

Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.

1 reference

12 December 2020

A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan

1 reference

12 December 2020

Mechanistic studies on metabolic interactions between gemfibrozil and statins

1 reference

12 December 2020

Statin safety: an overview and assessment of the data--2005.

1 reference

12 December 2020

In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes

1 reference

12 December 2020

Attenuation of inflammation and expansive remodeling by Valsartan alone or in combination with Simvastatin in high-risk coronary atherosclerotic plaques

1 reference

12 December 2020

Sustained reduction of serum cholesterol in low-dose 6-year simvastatin treatment with minimum side effects in 51,321 Japanese hypercholesterolemic patients

1 reference

12 December 2020

Clinical perspectives of statin-induced rhabdomyolysis

1 reference

12 December 2020

Safety of statins: focus on clinical pharmacokinetics and drug interactions

1 reference

12 December 2020

Statins and solid organ transplantation.

1 reference

12 December 2020

Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance

1 reference

12 December 2020

Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials

1 reference

12 December 2020

High-dose atorvastatin after stroke or transient ischemic attack

1 reference

12 December 2020

The interaction of diltiazem with simvastatin

1 reference

12 December 2020

The syndrome of rhabdomyolysis: complications and treatment

1 reference

12 December 2020

Asymptomatic hypothyroidism and statin-induced myopathy

1 reference

12 December 2020

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial

1 reference

12 December 2020

Combination statin-fibrate therapy: safety aspects

1 reference

12 December 2020

Statin-fibrate combination therapy

1 reference

12 December 2020

Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization

1 reference

12 December 2020

Striated muscle safety of ezetimibe/simvastatin (Vytorin).

1 reference

12 December 2020

Safety of perioperative statin use in high-risk patients undergoing major vascular surgery

1 reference

12 December 2020

Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin

1 reference

12 December 2020

Statin safety: an appraisal from the adverse event reporting system

1 reference

12 December 2020

Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?

1 reference

12 December 2020

Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients

1 reference

12 December 2020

Do Singapore patients require lower doses of statins? The SGH Lipid Clinic experience

1 reference

12 December 2020

Risk factors for statin-associated rhabdomyolysis

1 reference

12 December 2020

Safety and efficacy of statins in Asians

1 reference

12 December 2020

Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A.

1 reference

12 December 2020

Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study

1 reference

12 December 2020

ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins

1 reference

12 December 2020

Use of statins and fibrates in hyperlipidemic patients with neuromuscular disorders

1 reference

12 December 2020

Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force.

1 reference

12 December 2020

Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.

1 reference

12 December 2020

Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors

1 reference

12 December 2020

1 reference

12 December 2020

Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients

1 reference

12 December 2020

Risk-benefit of HMG-CoA reductase inhibitors in the treatment of HIV protease inhibitor-related hyperlipidaemia

1 reference

12 December 2020

Rhabdomyolysis and acute renal failure due to combination therapy with simvastatin and warfarin

1 reference

12 December 2020

Risks associated with statin therapy: a systematic overview of randomized clinical trials

1 reference

12 December 2020

The syndrome of rhabdomyolysis: Pathophysiology and diagnosis

1 reference

12 December 2020

Safety considerations with fibrate therapy

1 reference

12 December 2020

Enhancement of membrane fluidity in cholesterol-poor endothelial cells pre-treated with simvastatin

1 reference

12 December 2020

A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial

1 reference

12 December 2020

Tissue-selective action of pravastatin due to hepatocellular uptake via a sodium-independent bile acid transporter.

1 reference

12 December 2020

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

1 reference

12 December 2020

Results of two clinical trials on the safety and efficacy of pravastatin 80 and 160 mg per day.

1 reference

12 December 2020

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

1 reference

12 December 2020

Decreasing LDL cholesterol and medication cost with every-other-day statin therapy

1 reference

12 December 2020

Lovastatin, nicotinic acid, and rhabdomyolysis

1 reference

12 December 2020

Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin

1 reference

12 December 2020

SLCO1B1 variants and statin-induced myopathy--a genomewide study

1 reference

12 December 2020

Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations

1 reference

12 December 2020

Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment

1 reference

12 December 2020

Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders

1 reference

12 December 2020

Monday, Wednesday, and Friday dosing of rosuvastatin in patients previously intolerant to statin therapy

1 reference

12 December 2020

Molecular basis of statin-associated myopathy

1 reference

12 December 2020

Statin safety: a systematic review

1 reference

12 December 2020

Rhabdomyolysis from Simvastatin triggered by infection and muscle exertion

1 reference

12 December 2020

Effect of fluconazole on plasma fluvastatin and pravastatin concentrations

1 reference

12 December 2020

Role of multi-drug resistance-associated protein-1 transporter in statin-induced myopathy.

1 reference

12 December 2020

Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease

1 reference

12 December 2020

Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin

1 reference

12 December 2020

[Rhabdomyolysis in patients with preexisting myopathy, treated with antilipemic agents]

1 reference

12 December 2020

The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day

1 reference

12 December 2020

Lovastatin increases exercise-induced skeletal muscle injury

1 reference

12 December 2020

Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance

1 reference

12 December 2020

Safety considerations for statins

1 reference

12 December 2020

Efficacy and safety of simvastatin in Asian and non-Asian coronary heart disease patients: a comparison of the GOALLS and STATT studies.

1 reference

12 December 2020

Safety of niacin and simvastatin combination therapy

1 reference

12 December 2020

Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease

1 reference

12 December 2020

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

12 December 2020

Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The Alternate Day Versus Daily Dosing of Atorvastatin Study (ADDAS).

1 reference

12 December 2020

Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians?

1 reference

12 December 2020

Metabolism of the new immunosuppressor cyclosporin G by human liver cytochromes P450

1 reference

12 December 2020

Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin

1 reference

12 December 2020

Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease

1 reference

12 December 2020

Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation

1 reference

12 December 2020

Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV infection

1 reference

12 December 2020

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial

1 reference

12 December 2020

Structural mechanism for statin inhibition of HMG-CoA reductase

1 reference

12 December 2020

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

1 reference

12 December 2020

Genetic risk factors associated with lipid-lowering drug-induced myopathies

1 reference

12 December 2020

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

1 reference

12 December 2020

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

1 reference

12 December 2020

The safety of statins in clinical practice

1 reference

12 December 2020

Risk factors for rhabdomyolysis with simvastatin and atorvastatin

1 reference

12 December 2020

Safety of aggressive lipid management

1 reference

12 December 2020

New insights into the pharmacodynamic and pharmacokinetic properties of statins.

1 reference

12 December 2020

The role of coenzyme Q10 in statin-associated myopathy: a systematic review

1 reference

12 December 2020

Rhabdomyolysis with concurrent atorvastatin and diltiazem

1 reference

12 December 2020

Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression

1 reference

12 December 2020

Bacterial sepsis-induced rhabdomyolysis

1 reference

12 December 2020

Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms

1 reference

12 December 2020

Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans

1 reference

12 December 2020

Pharmacokinetics of the combination of fluvastatin and gemfibrozil

1 reference

12 December 2020

Cerivastatin and reports of fatal rhabdomyolysis

1 reference

12 December 2020

Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole

1 reference

12 December 2020

Genetic determinants of statin intolerance

1 reference

12 December 2020

Statin induced myopathy

1 reference

12 December 2020

Effects of once weekly rosuvastatin among patients with a prior statin intolerance

1 reference

12 December 2020

Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients

1 reference

12 December 2020

Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins

1 reference

12 December 2020

Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins

1 reference

12 December 2020

Genetic polymorphisms in cytochrome P450 enzymes: effect on efficacy and tolerability of HMG-CoA reductase inhibitors

1 reference

12 December 2020

Statin-associated myopathy

1 reference

12 December 2020

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions

1 reference

12 December 2020

Massive postoperative rhabdomyolysis following combined CABG/abdominal aortic replacement: a possible association with HMG-CoA reductase inhibitors

1 reference

12 December 2020

Coenzyme Q10 depletion: etiopathogenic or predisposing factor in statin associated myopathy?

1 reference

12 December 2020

Statin safety and drug interactions: clinical implications

1 reference

12 December 2020

Effect of lipid reduction on the progression of renal disease: a meta-analysis

1 reference

12 December 2020

Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin.

1 reference

12 December 2020

Statins may aggravate myasthenia gravis

1 reference

12 December 2020

Rhabdomyolysis triggered by cytomegalovirus infection in a heart transplant patient on concomitant cyclosporine and atorvastatin therapy

1 reference

12 December 2020

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

1 reference

12 December 2020

Involvement of organic anion transporting polypeptides in the toxicity of hydrophilic pravastatin and lipophilic fluvastatin in rat skeletal myofibres

1 reference

12 December 2020